- Home
- Publications
- Publication Search
- Publication Details
Title
The Adverse Effects of Sorafenib in Patients with Advanced Cancers
Authors
Keywords
-
Journal
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
Volume 116, Issue 3, Pages 216-221
Publisher
Wiley
Online
2014-12-15
DOI
10.1111/bcpt.12365
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Risk of Treatment-related Mortality with Sorafenib in Patients with Cancer
- (2014) Xin-Ji Zhang et al. Asian Pacific Journal of Cancer Prevention
- Sorafenib Dose Escalation Is Not Uniformly Associated With Blood Pressure Elevations in Normotensive Patients With Advanced Malignancies
- (2014) S Karovic et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients
- (2014) Olivier Huillard et al. Expert Opinion On Drug Safety
- Risk of cardiovascular toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis
- (2014) Omar Abdel-Rahman et al. Future Oncology
- Critical role of sorafenib exposure over time for its antitumor activity in thyroid cancer
- (2014) Audrey Bellesoeur et al. INVESTIGATIONAL NEW DRUGS
- Incidence and Risk of Sorafenib-Induced Hypertension: A Systematic Review and Meta-Analysis
- (2014) Yan Li et al. Journal of Clinical Hypertension
- Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
- (2014) Marcia S Brose et al. LANCET
- Management of Sorafenib-Related Adverse Events: A Clinician’s Perspective
- (2014) Marcia S. Brose et al. SEMINARS IN ONCOLOGY
- Management of Common Adverse Events in Patients Treated With Sorafenib: Nurse and Pharmacist Perspective
- (2014) Christine M. Walko et al. SEMINARS IN ONCOLOGY
- Sorafenib: from literature to clinical practice
- (2013) V. Di Marco et al. ANNALS OF ONCOLOGY
- Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients
- (2013) O Huillard et al. BRITISH JOURNAL OF CANCER
- Exposure–Toxicity Relationship of Sorafenib in Japanese Patients with Renal Cell Carcinoma and Hepatocellular Carcinoma
- (2013) Masahide Fukudo et al. CLINICAL PHARMACOKINETICS
- Correlation of skin toxicity and hypertension with clinical benefit in advanced hepatocellular carcinoma patients treated with sorafenib
- (2013) Sun Young Shin et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis
- (2013) T Funakoshi et al. JOURNAL OF HUMAN HYPERTENSION
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2012) Bassam Estfan et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib
- (2012) G. Dranitsaris et al. ANNALS OF ONCOLOGY
- A Phase II Trial of Intrapatient Dose-Escalated Sorafenib in Patients With Metastatic Renal Cell Carcinoma
- (2012) Robert Amato et al. Clinical Genitourinary Cancer
- Hypertension management in patients with renal cell cancer treated with anti-angiogenic agents
- (2012) P. Larochelle et al. Current Oncology
- Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice?
- (2012) Rodolfo Sacco et al. Expert Review of Anticancer Therapy
- Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies
- (2012) Austin Duffy et al. HEPATOLOGY
- Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib
- (2012) Taiga Otsuka et al. HEPATOLOGY RESEARCH
- Evidence for Therapeutic Drug Monitoring of Targeted Anticancer Therapies
- (2012) Bo Gao et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeted Therapies for Renal Cell Carcinoma: Review of Adverse Event Management Strategies
- (2012) T. Eisen et al. JNCI-Journal of the National Cancer Institute
- Variability of Sorafenib Toxicity and Exposure over Time: A Pharmacokinetic/Pharmacodynamic Analysis
- (2012) P. Boudou-Rouquette et al. ONCOLOGIST
- Sarcopenia Predicts Early Dose-Limiting Toxicities and Pharmacokinetics of Sorafenib in Patients with Hepatocellular Carcinoma
- (2012) Olivier Mir et al. PLoS One
- Early Sorafenib-Induced Toxicity Is Associated with Drug Exposure and UGTIA9 Genetic Polymorphism in Patients with Solid Tumors: A Preliminary Study
- (2012) Pascaline Boudou-Rouquette et al. PLoS One
- Side effects of anti-angiogenic drugs
- (2012) Francesca Elice et al. THROMBOSIS RESEARCH
- The Double Edged Sword of Bleeding and Clotting from VEGF Inhibition in Renal Cancer Patients
- (2012) Guru Sonpavde et al. Current Oncology Reports
- Meta-analysis of dermatological toxicities associated with sorafenib
- (2011) L. Zhang et al. CLINICAL AND EXPERIMENTAL DERMATOLOGY
- Cardiac side effects of molecular targeted therapies: Towards a better dialogue between oncologists and cardiologists
- (2011) Stephane Ederhy et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Sorafenib exposure decreases over time in patients with hepatocellular carcinoma
- (2011) Jennifer Arrondeau et al. INVESTIGATIONAL NEW DRUGS
- Noncardiac Vascular Toxicities of Vascular Endothelial Growth Factor Inhibitors in Advanced Cancer: A Review
- (2011) D. Keefe et al. ONCOLOGIST
- Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma
- (2010) S. Antoun et al. ANNALS OF ONCOLOGY
- Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America
- (2010) Walter M. Stadler et al. CANCER
- Risk of Arterial Thromboembolic Events With Sunitinib and Sorafenib: A Systematic Review and Meta-Analysis of Clinical Trials
- (2010) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib
- (2010) Lokesh Jain et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors
- (2010) Michael L. Maitland et al. JNCI-Journal of the National Cancer Institute
- Rapid Development of Hypertension by Sorafenib: Toxicity or Target?
- (2009) B. D. Humphreys et al. CLINICAL CANCER RESEARCH
- Sorafenib-Related Hand-Foot Skin Reaction Improves, Not Worsens, with Continued Treatment
- (2009) K. T. Flaherty et al. CLINICAL CANCER RESEARCH
- Hand-Foot Skin Reaction Increases with Cumulative Sorafenib Dose and with Combination Anti-Vascular Endothelial Growth Factor Therapy
- (2009) N. S. Azad et al. CLINICAL CANCER RESEARCH
- Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
- (2009) Jorg Hartmann et al. CURRENT DRUG METABOLISM
- Sorafenib
- (2009) Gillian M. Keating et al. DRUGS
- VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management
- (2009) Hassane Izzedine et al. EUROPEAN JOURNAL OF CANCER
- Thrombotic Events in Patients With Cancer Receiving Antiangiogenesis Agents
- (2009) Maurizio Zangari et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
- (2009) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials
- (2009) Youjin Je et al. LANCET ONCOLOGY
- Cardiovascular toxicity caused by cancer treatment: strategies for early detection
- (2009) Renske Altena et al. LANCET ONCOLOGY
- Adverse effects of anticancer agents that target the VEGF pathway
- (2009) Helen X. Chen et al. Nature Reviews Clinical Oncology
- Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma
- (2009) R. C. Kane et al. ONCOLOGIST
- Hand-Foot Syndrome (Hand-Foot Skin Reaction, Palmar-Plantar Erythrodysesthesia): Focus on Sorafenib and Sunitinib
- (2009) Adam D. Lipworth et al. ONCOLOGY
- Risk of hand-foot skin reaction with sorafenib: A systematic review and meta-analysis
- (2008) David Chu et al. ACTA ONCOLOGICA
- Sorafenib for Metastatic Renal Cancer
- (2008) Rachel P. Riechelmann et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Combination Targeted Therapy With Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity
- (2008) Nilofer S. Azad et al. JOURNAL OF CLINICAL ONCOLOGY
- Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma
- (2008) Manuela Schmidinger et al. JOURNAL OF CLINICAL ONCOLOGY
- A Preeclampsia-like Syndrome Characterized by Reversible Hypertension and Proteinuria Induced by the Multitargeted Kinase Inhibitors Sunitinib and Sorafenib
- (2008) T. V. Patel et al. JNCI-Journal of the National Cancer Institute
- Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis
- (2008) Shenhong Wu et al. LANCET ONCOLOGY
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
- (2008) Scott M. Wilhelm et al. MOLECULAR CANCER THERAPEUTICS
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started